1-20 of 2,843 results for subject:Epilepsy
Librarians' tools
- Search time
- 0.277 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:Epilepsy
- We searched for
- subject_t:Epilepsy OR subject_t:"Lennox-Gastaut syndrome" OR subject_ses:9971
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits of free dental repairs for teeth damaged by seizures.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits of free dental repairs for teeth damaged by seizures.
I refer the Hon Member to the answer given on 9 June in response to Question 2619.
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the adequacy of the seizure assessment criteria contained within the National Framework for Children and Young People's Continuing Care – Decision Support Tool, published in 2016; and whether she has plans to...
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the adequacy of the seizure assessment criteria contained within the National Framework for Children and Young People's Continuing Care – Decision Support Tool, published in 2016; and whether she has plans to...
To ask the Secretary of State for Health and Social Care, what measures are in place to ensure timely access to care for individuals with epilepsy.
To ask the Secretary of State for Health and Social Care, what measures are in place to ensure timely access to care for individuals with epilepsy.
I am grateful that the Department has moved swiftly to identify the issues with the supply of Bedrolite from Bedrocan, the company in real difficulty in the Netherlands. I understand that there is confidence in supplies until 2027, but my constituents say that that may depend on whether someone has an NHS or a private prescription. Would the Minister and his officials meet me to go through these processes, some of which, from my constituents’ experience, have been very bureaucratic?
I am grateful that the Department has moved swiftly to identify the issues with the supply of Bedrolite from Bedrocan, the company in real difficulty in the Netherlands. I understand that there is confidence in supplies until 2027, but my constituents say that that may depend on whether someone has an NHS or a private prescription. Would the Minister and his officials meet me to go through these processes, some of which, from my constituents’ experience, have been very bureaucratic?
My hon. Friend makes a really important point. Ensuring sustainable supply for so sensitive a medicine to address epilepsy is uppermost in my mind. It is a live situation, I am working at pace with officials, and I will update her accordingly.
My hon. Friend makes a really important point. Ensuring sustainable supply for so sensitive a medicine to address epilepsy is uppermost in my mind. It is a live situation, I am working at pace with officials, and I will update her accordingly.
To ask the Secretary of State for Health and Social Care, if she will review the policy whereby drug-resistant epilepsy does not qualify within free NHS flu vaccinations.
To ask the Secretary of State for Health and Social Care, if she will review the policy whereby drug-resistant epilepsy does not qualify within free NHS flu vaccinations.
To ask the Secretary of State for Health and Social Care, if she will take diplomatic and regulatory steps with the Dutch Ministry of Health and the Medicines and Healthcare products Regulatory Agency (MHRA) to secure the emergency export release of existing Bedrolite stockpiles following the insolvency of Bedrocan; and...
To ask the Secretary of State for Health and Social Care, if she will take diplomatic and regulatory steps with the Dutch Ministry of Health and the Medicines and Healthcare products Regulatory Agency (MHRA) to secure the emergency export release of existing Bedrolite stockpiles following the insolvency of Bedrocan; and...
The British Embassy in The Hague is in contact with the Dutch Ministry of Health, Welfare and Sport to understand the reported changes affecting Bedrocan products and the potential impact on United Kingdom patients who currently rely on them.
Clinical decisions regarding an individual patient are a matter for their responsible clinician, who are best placed to assess and manage patient risk.
To ask His Majesty's Government whether they intend to seek an urgent agreement with the government of the Netherlands, similar to the arrangement made in 2021 for patients with NHS prescriptions, to ensure that patients with private prescriptions do not lose access to Bedrolite as treatment for their epileptic seizures.
To ask His Majesty's Government whether they intend to seek an urgent agreement with the government of the Netherlands, similar to the arrangement made in 2021 for patients with NHS prescriptions, to ensure that patients with private prescriptions do not lose access to Bedrolite as treatment for their epileptic seizures.
The British Embassy in The Hague is in contact with the Dutch Ministry of Health, Welfare and Sport to understand the reported changes affecting the manufacturer of Bedrolite and the potential impact on UK-based patients who currently rely on this product.
The Government recognises the importance of uninterrupted access to medicines for patients, but clinical decisions regarding an individual patient will remain a matter for their responsible clinicians, who are best placed to assess and manage patient risk.
To ask His Majesty's Government what urgent action they plan to take, in consultation with the government of the Netherlands, to secure continued supplies of Bedrolite for patients with severe epilepsy for whom it is the only effective treatment.
To ask His Majesty's Government what urgent action they plan to take, in consultation with the government of the Netherlands, to secure continued supplies of Bedrolite for patients with severe epilepsy for whom it is the only effective treatment.
The British Embassy in The Hague is in contact with the Dutch Ministry of Health, Welfare and Sport to understand the reported changes affecting the manufacturer of Bedrolite and the potential impact on UK-based patients who currently rely on this product.
The Government recognises the importance of uninterrupted access to medicines for patients, but clinical decisions regarding an individual patient will remain a matter for their responsible clinicians, who are best placed to assess and manage patient risk.
To ask the Secretary of State for Health and Social Care, whether the recommendations of the National Maternity and Neonatal Taskforce will incorporate the standards set out in the NHS Maternal Care Bundle for women with epilepsy.
To ask the Secretary of State for Health and Social Care, whether the recommendations of the National Maternity and Neonatal Taskforce will incorporate the standards set out in the NHS Maternal Care Bundle for women with epilepsy.
The Government recognises the significance of epilepsy as a cause of maternal mortality, highlighted by the latest MBRRACE-UK report. NHS England's Maternal Care Bundle (MCB), informed by evidence from MBRRACE-UK, includes actions to support the safe management and monitoring of anti-seizure medication, improve access to specialist epilepsy and maternal medicine expertise, and strengthen multidisciplinary care for pregnant women with epilepsy.
All National Health Service trusts providing maternity services are expected to implement the Maternal Care Bundle in full by March 2027. NHS trusts are also incentivised to implement the bundle through Year 8 of the Maternity Incentive Scheme and must be able to evidence a plan for achieving full implementation by the national deadline.
The National Maternity and Neonatal Taskforce is currently considering a wide range of evidence to inform the national action plan, including the standards set out in the Maternal Care Bundle. Its Charity and Third Sector expert reference group includes representation from Epilepsy Action.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that pregnant women with epilepsy have access to specialist epilepsy and maternal medicine services.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that pregnant women with epilepsy have access to specialist epilepsy and maternal medicine services.
The Government recognises the significance of epilepsy as a cause of maternal mortality, highlighted by the latest MBRRACE-UK report. NHS England's Maternal Care Bundle (MCB), informed by evidence from MBRRACE-UK, includes actions to support the safe management and monitoring of anti-seizure medication, improve access to specialist epilepsy and maternal medicine expertise, and strengthen multidisciplinary care for pregnant women with epilepsy.
All National Health Service trusts providing maternity services are expected to implement the Maternal Care Bundle in full by March 2027. NHS trusts are also incentivised to implement the bundle through Year 8 of the Maternity Incentive Scheme and must be able to evidence a plan for achieving full implementation by the national deadline.
The National Maternity and Neonatal Taskforce is currently considering a wide range of evidence to inform the national action plan, including the standards set out in the Maternal Care Bundle. Its Charity and Third Sector expert reference group includes representation from Epilepsy Action.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential implications for her policies of the latest MBRRACE Report on epilepsy-related maternal deaths; and what steps she is taking to reduce such deaths.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential implications for her policies of the latest MBRRACE Report on epilepsy-related maternal deaths; and what steps she is taking to reduce such deaths.
The Government recognises the significance of epilepsy as a cause of maternal mortality, highlighted by the latest MBRRACE-UK report. NHS England's Maternal Care Bundle (MCB), informed by evidence from MBRRACE-UK, includes actions to support the safe management and monitoring of anti-seizure medication, improve access to specialist epilepsy and maternal medicine expertise, and strengthen multidisciplinary care for pregnant women with epilepsy.
All National Health Service trusts providing maternity services are expected to implement the Maternal Care Bundle in full by March 2027. NHS trusts are also incentivised to implement the bundle through Year 8 of the Maternity Incentive Scheme and must be able to evidence a plan for achieving full implementation by the national deadline.
The National Maternity and Neonatal Taskforce is currently considering a wide range of evidence to inform the national action plan, including the standards set out in the Maternal Care Bundle. Its Charity and Third Sector expert reference group includes representation from Epilepsy Action.
To ask the Secretary of State for Health and Social Care, whether she is taking steps to implement the recommendations in the latest MBRRACE Report relating to the care of women with epilepsy, including through the NHS Maternal Care Bundle.
To ask the Secretary of State for Health and Social Care, whether she is taking steps to implement the recommendations in the latest MBRRACE Report relating to the care of women with epilepsy, including through the NHS Maternal Care Bundle.
The Government recognises the significance of epilepsy as a cause of maternal mortality, highlighted by the latest MBRRACE-UK report. NHS England's Maternal Care Bundle (MCB), informed by evidence from MBRRACE-UK, includes actions to support the safe management and monitoring of anti-seizure medication, improve access to specialist epilepsy and maternal medicine expertise, and strengthen multidisciplinary care for pregnant women with epilepsy.
All National Health Service trusts providing maternity services are expected to implement the Maternal Care Bundle in full by March 2027. NHS trusts are also incentivised to implement the bundle through Year 8 of the Maternity Incentive Scheme and must be able to evidence a plan for achieving full implementation by the national deadline.
The National Maternity and Neonatal Taskforce is currently considering a wide range of evidence to inform the national action plan, including the standards set out in the Maternal Care Bundle. Its Charity and Third Sector expert reference group includes representation from Epilepsy Action.
Bedrolite is a medication for those with a very rare form of epilepsy. There are, I understand, four private prescriptions and three NHS prescriptions in the country. It is made by a company based in the Netherlands called Bedrocan, which was in the news at the weekend because it is...
Bedrolite is a medication for those with a very rare form of epilepsy. There are, I understand, four private prescriptions and three NHS prescriptions in the country. It is made by a company based in the Netherlands called Bedrocan, which was in the news at the weekend because it is...
This is a really serious matter, and my hon. Friend is right to bring it to the Floor of the House, because it is of huge concern to the families affected. She said that she had written to the Secretary of State and the relevant Minister. I am not sure...
This is a really serious matter, and my hon. Friend is right to bring it to the Floor of the House, because it is of huge concern to the families affected. She said that she had written to the Secretary of State and the relevant Minister. I am not sure...
To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the potential impact of levels of epilepsy medication availability on patient safety.
To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the potential impact of levels of epilepsy medication availability on patient safety.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve maternity care for women with epilepsy.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve maternity care for women with epilepsy.
On 6 January 2026, NHS England published the Maternal Care Bundle, setting out best practice standards to tackle the leading causes of maternal death including epilepsy, thrombosis, mental health, and haemorrhage.
The National Maternity and Neonatal Taskforce is developing an action plan, to be published by the end of this year, to improve maternity and neonatal care across the country. All women and babies have a right to safe, personalised, and equitable care, which takes account of their individual needs, conditions, and preferences.
The taskforce and its supporting expert reference groups have been set up to ensure a representative breadth of voices inform its approach. The taskforce is comprised of experts and key stakeholders including families, clinicians, academics, royal colleges, charities, and grass-root organisations, including representation from Epilepsy Action, as well as those who can speak to health equity and international expertise.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve maternity care for women with epilepsy.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve maternity care for women with epilepsy.
On 6 January 2026, NHS England published the Maternal Care Bundle, setting out best practice standards to tackle the leading causes of maternal death including epilepsy, thrombosis, mental health, and haemorrhage.
The National Maternity and Neonatal Taskforce is developing an action plan, to be published by the end of this year, to improve maternity and neonatal care across the country. All women and babies have a right to safe, personalised, and equitable care, which takes account of their individual needs, conditions, and preferences.
The taskforce and its supporting expert reference groups have been set up to ensure a representative breadth of voices inform its approach. The taskforce is comprised of experts and key stakeholders including families, clinicians, academics, royal colleges, charities, and grass-root organisations, including representation from Epilepsy Action, as well as those who can speak to health equity and international expertise.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that people with epilepsy are represented in the work of the Maternity and Neonatal Taskforce.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that people with epilepsy are represented in the work of the Maternity and Neonatal Taskforce.
On 6 January 2026, NHS England published the Maternal Care Bundle, setting out best practice standards to tackle the leading causes of maternal death including epilepsy, thrombosis, mental health, and haemorrhage.
The National Maternity and Neonatal Taskforce is developing an action plan, to be published by the end of this year, to improve maternity and neonatal care across the country. All women and babies have a right to safe, personalised, and equitable care, which takes account of their individual needs, conditions, and preferences.
The taskforce and its supporting expert reference groups have been set up to ensure a representative breadth of voices inform its approach. The taskforce is comprised of experts and key stakeholders including families, clinicians, academics, royal colleges, charities, and grass-root organisations, including representation from Epilepsy Action, as well as those who can speak to health equity and international expertise.
To ask the Minister for Women and Equalities, what assessment she has made of the potential impact of the use of a driving licence as an automatic screening requirement by potential employers on (a) jobseekers with epilepsy and (b) other disabled jobseekers.
To ask the Minister for Women and Equalities, what assessment she has made of the potential impact of the use of a driving licence as an automatic screening requirement by potential employers on (a) jobseekers with epilepsy and (b) other disabled jobseekers.